Bayer vs Johnson & Johnson stock
Side by side in plain words: who keeps more of its sales, grows faster, costs less and owes less.
Johnson & Johnson is more profitable, grows faster, is cheaper for its profits and has less debt.
Side by side
| Bayer | Johnson & Johnson | |
|---|---|---|
| €55.5 billion | $688 billion | |
| -7.9% | 28.5% | |
| −3.5% | +2.7% | |
| No profit yet | 25.7× | |
| 15.5 years | 0.7 years | |
| -1.0% | 21.0% | |
| 0.2% | 2.3% |
How we compare
Four contests with the same rules as each stock page: profit kept from sales (higher wins), yearly sales growth across the last reports, up to five years (higher wins), price per unit of yearly profit (lower P/E wins; a company without profit loses) and debt in years of earnings (lower wins). A winner is only named when both companies have the number.
More comparisons: Bayer vs Eli Lilly · Bayer vs Merck & · Bayer vs Roche · Johnson & Johnson vs Becton, Dickinson and · Johnson & Johnson vs Bristol-Myers Squibb · Johnson & Johnson vs Boston Scientific · Johnson & Johnson vs CSL